Last reviewed · How we verify
Regorafenib and DIBIRI
Regorafenib is a multi-kinase inhibitor that blocks tumor angiogenesis and growth signaling, while DIBIRI (dinitro-irinotecan) is a lipophilic prodrug of irinotecan that enhances drug delivery to tumors.
Regorafenib is a multi-kinase inhibitor that blocks tumor angiogenesis and growth signaling, while DIBIRI (dinitro-irinotecan) is a lipophilic prodrug of irinotecan that enhances drug delivery to tumors. Used for Metastatic colorectal cancer (Phase 3 trial).
At a glance
| Generic name | Regorafenib and DIBIRI |
|---|---|
| Also known as | Drug: Irinotecan, Procedure: TACE, Device: drug eluting-bead |
| Sponsor | Sun Yat-sen University |
| Drug class | Multi-kinase inhibitor (regorafenib) combined with topoisomerase I inhibitor (DIBIRI) |
| Target | VEGFR, FGFR, KIT, RET, RAF (regorafenib); Topoisomerase I (DIBIRI/irinotecan) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Regorafenib inhibits multiple receptor tyrosine kinases (VEGFR, FGFR, KIT, RET, RAF) involved in tumor angiogenesis and proliferation. DIBIRI is a nanoparticle-bound formulation of irinotecan designed to improve tumor accumulation and reduce systemic toxicity. The combination leverages anti-angiogenic and cytotoxic mechanisms to target colorectal cancer.
Approved indications
- Metastatic colorectal cancer (Phase 3 trial)
Common side effects
- Hand-foot skin reaction
- Diarrhea
- Fatigue
- Hypertension
- Neutropenia
Key clinical trials
- Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Regorafenib and DIBIRI CI brief — competitive landscape report
- Regorafenib and DIBIRI updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI